| Methods |
3‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐115 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
All patients: n=22; mean age=59(11) years;
Cilazapril 2.5 mg: n=6; baseline sitting SBP=173(22) mm Hg, DBP=110(7.4) mm Hg;
Placebo: n=5; baseline sitting SBP=159(27) mm Hg, DBP=101(13.4) mm Hg |
| Interventions |
Cilazapril 2.5 mg once daily;
Placebo;
taken at approximately 8 AM |
| Outcomes |
Trough sitting SBP/DBP using oscillometric device (Dinamap);
Trough standing SBP/DBP using oscillometric device (Dinamap) |
| Notes |
BP change and SD of change not reported, endpoint BP and SE reported; calculated endpoint SD from N and SE; endpoint SD values are too low; imputed SBP SD of change from baseline SBP SD of change, imputed overall trial mean DBP SD of change; BP data from Table 2, p. 455; Jadad score=2; funding source= Roche Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
